Cargando…

In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies.

A brain tumour-associated marker, urokinase (UK), was investigated using rabbit anti-UK polyclonal and murine anti-UK monoclonal antibodies, which were prepared by immunization with low molecular weight UK (LMW-UK) and high molecular weight urokinase (HMW-UK) synthetic peptide respectively. The poly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abaza, M. S., Shaban, F. A., Narayan, R. K., Atassi, M. Z.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group\|1 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063246/ https://www.ncbi.nlm.nih.gov/pubmed/9862567

Ejemplares similares

In vitro Efficacy of Anti‐glial Fibrillary Acidic Protein Monoclonal Antibodies against Human Malignant Glioma Cell Lines
por: Abaza, Mohamed‐Salah I., et al.
Publicado: (1997)

Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.
por: Foucré, D., et al.
Publicado: (1991)

Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma
por: Wang, Shenqi, et al.
Publicado: (2016)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines
por: Baldini, Enke, et al.
Publicado: (2022)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor
por: Albo, D, et al.
Publicado: (2000)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
por: Zhu, Ran, et al.
Publicado: (2022)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
Publicado: (1984)

Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis
por: Lee, Ji-Hye, et al.
Publicado: (2014)

Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis
por: Guiducci, S, et al.
Publicado: (2005)

The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type
Publicado: (1986)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
por: Özdirik, Burcin, et al.
Publicado: (2020)

Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: Role of oxygenation status and tumour size
por: Weinmann, M, et al.
Publicado: (2002)

Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
por: Heynekamp, Justin J, et al.
Publicado: (2006)

Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
por: Ierodiakonou, Despo, et al.
Publicado: (2016)

Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells
por: de Geus, Susanna WL, et al.
Publicado: (2017)

Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU)
por: Hosen, S. M. Zahid, et al.
Publicado: (2022)

Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.
por: Cantero, D., et al.
Publicado: (1997)

Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts
por: Chao, Shih-Chun, et al.
Publicado: (2011)

Urokinase-type plasminogen activator receptor in IgA nephropathy
por: Ahn, Shin-Young, et al.
Publicado: (2014)

Urokinase-type Plasminogen Activator Induces Neurorepair in the Ischemic Brain
por: Merino, Paola, et al.
Publicado: (2018)

Tumour Microenvironments Induce Expression of Urokinase Plasminogen Activator Receptor (uPAR) and Concomitant Activation of Gelatinolytic Enzymes
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Immunohistochemical localization of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and α2-antiplasmin in human corneal perforation: a case report
por: Sugioka, Koji, et al.
Publicado: (2012)

Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer
por: Baart, V. M., et al.
Publicado: (2020)

Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
por: van Oort, Pouline M., et al.
Publicado: (2019)

The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review
por: Tucker, Torry A., et al.
Publicado: (2021)

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
por: Knoop, A., et al.
Publicado: (1998)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
por: Luo, Shengyuan, et al.
Publicado: (2022)

HAX1 Augments Cell Proliferation, Migration, Adhesion, and Invasion Induced by Urokinase-Type Plasminogen Activator Receptor
por: Mekkawy, Ahmed H., et al.
Publicado: (2012)

Plasminogen activator, urokinase enhances the migration, invasion, and proliferation of colorectal cancer cells by activating the Src/ERK pathway
por: Ding, Yuanyi, et al.
Publicado: (2022)

Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
por: Kennedy, S., et al.
Publicado: (1998)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells
Publicado: (1987)

immunocytochemical localization of urokinase-type plasminogen activator in lewis lung carcinoma
por: Skriver, L, et al.
Publicado: (1984)

Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants
por: Haastrup, Eva, et al.
Publicado: (2014)

Urokinase-type plasminogen activator: a new target for male contraception?
por: Qin, Ying, et al.
Publicado: (2015)

Urokinase-Type Plasminogen Activator Deficiency Promotes Neoplasmatogenesis in the Colon of Mice()()()
por: Karamanavi, Elisavet, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ef32fqdj3dtqvngr67fbm69837